C12N 9/6459
T-plasminogen activator , i.e. tpa
Official title: {t-plasminogen activator (3.4.21.68), i.e. tPA}
C12N9/6459 (T-plasminogen activator , i.e. tpa) appears on 332 US grants and 127 published applications in this corpus.
Search patents in C12N- Granted patents
- 332
- Published applications
- 127
- Assignees
- 140
- Inventors
- 543
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 3 | 0 |
| 1988 | 6 | 0 |
| 1989 | 5 | 0 |
| 1990 | 22 | 0 |
| 1991 | 21 | 0 |
| 1992 | 27 | 0 |
| 1993 | 25 | 0 |
| 1994 | 12 | 0 |
| 1995 | 15 | 0 |
| 1996 | 18 | 0 |
| 1997 | 26 | 0 |
| 1998 | 26 | 0 |
| 1999 | 18 | 0 |
| 2000 | 10 | 0 |
| 2001 | 9 | 1 |
| 2002 | 8 | 6 |
| 2003 | 8 | 9 |
| 2004 | 5 | 13 |
| 2005 | 5 | 6 |
| 2006 | 5 | 9 |
| 2007 | 3 | 5 |
| 2008 | 3 | 3 |
| 2009 | 2 | 6 |
| 2010 | 1 | 4 |
| 2011 | 4 | 4 |
| 2012 | 4 | 7 |
| 2013 | 2 | 7 |
| 2014 | 6 | 7 |
| 2015 | 4 | 7 |
| 2016 | 2 | 2 |
| 2017 | 5 | 7 |
| 2018 | 2 | 3 |
| 2019 | 4 | 2 |
| 2020 | 1 | 4 |
| 2021 | 0 | 0 |
| 2022 | 6 | 3 |
| 2023 | 1 | 5 |
| 2024 | 1 | 3 |
| 2025 | 1 | 3 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- PD1-based vaccination composition and methods thereof2 Jun 2026US 12,642,845 B2Versitech Limited
- Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase31 Mar 2026US 12,590,301 B2Thrombolytic Science, Inc.
- Thrombolytic and neuro/vasculoprotective nanoconjugates9 Sep 2025US 12,409,147 B2The Cleveland Clinic Foundation
- Treatment for airway cast obstruction10 Sep 2024US 12,084,695 B2National Jewish Health
- Mirac proteins8 Aug 2023US 11,718,844 B2BioAtla, Inc.
- Thrombolytic and neuro/vasculoprotective nanoconjugates8 Jan 2026US 2026/0007614 A1The Cleveland Clinic Foundation
- Ultrasound-mediated gene therapy for deep vein thrombosis and post-thrombotic syndrome3 Jul 2025US 2025/0213695 A1Cedars-Sinai Medical Center
- Treatment for airway cast obstruction10 Apr 2025US 2025/0115891 A1National Jewish Health
- Targeted degradation and removal of amyloid beta plaques for the prevention and treatment of alzheimer’s diseases via engineered nano-scavenger exosomes13 Mar 2025US 2025/0082775 A1Santa Clara University
- Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease31 Oct 2024US 2024/0360431 A1Sichuan Real&Best Biotech Co., Ltd.
Most cited
By later US patents
- Method for dominant selection in eucaryotic cells277US 5,122,464 ACelltech Limited, a British Company · 1992
- Vectors and methods for transformation of eucaryotic cells219US 4,740,461 AGenetics Institute, Inc. · 1988
- Method for making variant secreted proteins with altered properties199US 5,223,408 AGenentech, Inc. · 1993
- Method for culturing Chinese hamster ovary cells186US 5,633,162 AGlaxo Wellcome Inc. · 1997
- Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes185US 5,316,931 ABiosource Genetics Corporation · 1994